Abstract. In vivo studies using single-photon emission tomography (SPET) and positron emission tomography have shown an age-related decline in the number of striatal dopamine transporters in healthy subjects. We examined ten healthy subjects and 33 de novo patients with Parkinson's disease (PD) using [123I]213-carbomethoxy-313-(4-iodophenyl)tropane ([123I]~-CIT) SPET. A clear age-related loss of dopamine transporters was found in the healthy subjects. In the PD group, controlling for the contribution of disease severity, we found a small (compared with controls) but significant decrease with aging, though only in the ipsilateral regions. This aging effect was especially pronounced in younger patients. We conclude that the use of age-correct SPET data in PD, based on studies with healthy subjects, may lead to an underor an overestimation of the striatal binding measures.
Introduction
Post-mortem studies have shown an age-related decline in the number of presynaptic striatal dopamine (DA) transporters in healthy subjects, indicating a loss of dopaminergic nigral neurons with increasing age [1] [2] [3] . With positron emission tomography (PET) and singlephoton emission tomography (SPET), in vivo evaluation of age effects on the integrity of the presynaptic nigrostriatal dopaminergic system has become possible.
In SPET studies using
[123I]2~3-carbomethoxy-313-(4-iodophenyl)tropane ([123I]~-CIT), which has been shown
Correspondence to: G. Tissingh, Academisch Ziekenhuis Vrije Universiteit, Department of Neurology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands to be sensitive to dopaminergic presynaptic degeneration [4] , Van Dyck et al. confirmed in 28 healthy subjects the post-mortem reports on DA transporter loss with increasing age [5] .
Two in vivo studies have reported on the effect of aging in Parkinson's disease (PD), without controlling for disease severity and dopaminergic medication. Using 11C-nomifensine PET, Tedroff et al. [6] did not find any significant decline in binding with age (n=6), whereas Marek et al. [71, using [123I]~-CIT SPET, did (n=8).
In this study we investigated possible age effects on the striatal DA transporter binding in healthy subjects and a large group of de novo patients with PD by means of [123I][3-CIT SPET, taking into account the severity of PD.
Materials and methods
Subjects. Thirty-three early and non-medicated PD patients and ten healthy controls were investigated. The patients ranged in age from 32 to 68 years (three were aged 30-39, seven 40-49, 16 50-59, and seven 60-69) and the controls ranged in age from 20 to 65 years (three were 20-29, one 30-39, one 40-49, two 50-59, and three 60-69). PD was diagnosed according to the criteria of the U.K. Parkinson's Disease Society Brain Bank. The severity of the motor signs was assessed according to the Unified Parkinson's Disease Rating Scale (UPDRS). Mean disease duration was 2.5 years (SD=I.3), with a mean Hoehn and Yahr stage of 1.7 (SD=0.6) ( Table 1) .
The healthy volunteers were free from any neurological or psychiatric disease and were not taking drugs known to affect the dopaminergic system. All subjects gave written informed consent to the research protocol, which was approved by the medical ethical committee of the hospital.
SPET camera and reconstruction. For SPET studies a brain-dedicated camera, the Strichman Medical Equipment 810X system was used. This multidetector camera contains 12 high-resolution focussing collimators, arranged in six pairs opposite to each other. The transaxial resolution of this camera is 7.6 mm full-width atquisition took place in a 128x128 matrix. Reconstruction was always carried out according to the manufacturer's protocol package. The measured concentration of radioactivity was expressed in Strichman Medical Units (SMUs; 1 SMU=100 Bq/ml as specified by the manufacturer).
SPET experiments. The subjects received potassium iodide orally (three doses of 40 mg on the day before imaging and 80 mg just before imaging) in order to block thyroid uptake of free radioactive iodine. [~2?I]~-CIT (specific activity >185 Bq/nmol; radiochemical purity >99%) was injected intravenously at an approximate dose of 110 MBq. 123I labelling was performed by Amersham Cygne BV (Technical University Eindhoven, The Netherlands), using the trimethylstannyl precursor of ~-CIT obtained from Research Biochemicals International (Natick, Mass., USA). SPET image acquisition was performed at 24 h post injection. Slices were acquired during 300-s periods from the orbitromeatal line to the vertex using an interslice distance of 10 mm. Data processing. For analysis of striatal [123I][3-CIT binding, the ratio of specific to non-specific binding was calculated by summing two transversal slices representing the most intense striatal binding. A standard region of interest (ROI) template, constructed according to a stereotactic atlas and including regions for putamen, caudate nucleus and occipital cortex, and additional ROIs for the entire striatum, was placed bilaterally on the summed image as previously described [8] . Estimates of specific striatal binding were made by subtracting occipital counts from striatal counts. The ratio of specific to non-specific striatal [123I]~-CIT binding was then calculated, by dividing specific striatal binding by occipital binding [7] .
Statistics. Analysis of variance (ANOVA), with age and gender as co-variates, was used to compare the regional SPET measures in the PD patients and healthy controls. The relationship between the binding of 1123I][3-CIT and age was examined by linear regression analysis. Significance was assessed at the P<0.05 level.
Results
There was no significant difference in age between the patients and the control group (Mann-Whitney test). A significant difference in striatal [I23I][3-CIT binding measures between males and females could not be detected either in the patient or in the control group (ANOVA, with age and UPDRS score as co-variates). The ratios of specific to non-specific [123I]~-CIT binding in all studied regions were significantly lower in the patient group (Table 1) .
Linear regression analysis was performed with the ipsilateral and contralateral putamen, caudate nucleus and striatum as dependent variables, and with age and UP-DRS motor score as independent variables (Table 2, Fig.  1 ).
Within the control group, age accounted for a great and significant part of the variance. In the PD group, controlling for the contribution of the severity of PD, age accounted for a smaller, though significant part of the variance in the ipsilateral, but not in the contralateral regions. Furthermore, when the patients were split into three groups with approximately equal class widths [I: 32-45 years (n=7); II: 46-56 years (n=15); III: 57-68 years (n=ll)], analyses of variance (UPDRS score as a covariate) showed that the ipsilateral striatal binding measures were higher in group I than in groups II and III (I-II: P<0.05, R2=0.51; I-III: P<0.05, R2=0.41), but not in group II compared with group lII, whereas the contralateral striatal SPET measures were not significantly different between the three subgroups.
Discussion
The results of this study clearly show that [1%I]~-CIT binding in the striatum in healthy subjects decreases with age, accounting for a loss of approximately 10% per decade. Although the sample size of the examined healthy controls is rather small, and does not allow an exact estimation of the rate of loss of DA transporters per decade in normal aging, our results are in agreement with human post-mortem observations [1] [2] [3] 9] and earlier imaging studies with [123I]~-CIT, finding a loss of 8% per decade [5] . Others have found decreases varying from 3.3% to 7% per decade [10] [11] [12] . The use of different ligands and techniques to examine the dopaminergic system, methodological differences, and differences regarding the age range of the control groups might underlie the discrepancies between the reported percentages. For example, Ishikawa et al. [12] found a normal aging effect using [~23I][3-CIT-FP SPET, but not with [~SF]FDOPA PET in the same subjects. Others [13] showed that the effects of aging may be non-linear, i.e. relatively rapid rates of decline during young adulthood (less than 30 years old).
Interestingly, in 33 de novo PD patients, controlling for the contribution of disease severity, we found a small (compared with the controls) though significant influence of age on [123I]13-CIT binding, but only in the ipsilateral regions. This aging effect was also more pronounced in the patients aged 32-45 years than in those older than 45 years. As mentioned earlier, Marek et al. [7] , using [123I][3-CIT, found a significant decline in striatal binding with age in PD patients (n=8), while Tedroff et al. [6] failed to find such a decline using 11C-nomifensine (n=6). However, in these studies, involving a relatively small number of patients, neither the severity of PD nor the medication was taken into account, which makes it difficult to estimate reliably the contribution of age.
The absence of a significant aging effect in the contralateral regions is probably explained by a more severe, pathological loss of DA transporters compared with the ipsilateral side, masking the age-related loss.
In summary, the present study shows a clear age-related loss of DA transporters in healthy subjects. In de novo PD patients, however, a small decrease with aging was visible only in the ipsilateral striatum, when controlling for disease severity, and this aging effect was especially evident in the younger patients. These findings strongly suggest that the use of age-corrected SPET data, based on studies with healthy controls, may lead to false conclusions regarding the binding capacity and by inference the number of DA transporters. In the case of older patients, the use of such age-correct SPET measures leads to an underestimation of the number of DA transporters, whereas the SPET measures of an early PD patient of age 30 will be less easily recognized as abnormal because of an overestimation of the binding capacity.
